| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Metastasis Research Program, Michigan Cancer Foundation, Department of Pathology and Radiation Oncology, Wayne State University, School of Medicine, Detroit, Michigan 48201
Galectin-3 (Gal-3) is a ß-galactoside-binding protein with Mr 
30,000. Cell surface Gal-3 is postulated to be involved in homotypic aggregation of tumor cells in the circulation during metastasis through attachment to a complementary serum glycoprotein(s), which serves as a cross-linking bridge between adjacent cells. To test this hypothesis a recombinant strain of baculovirus encoding Gal-3 was used to infect Sf9 insect cells, which lack endogenous Gal-3. Immunoblotting and indirect immunofluorescence studies revealed that the infection with recombinant virus conferred Gal-3 expression on Sf9 cells, and the Gal-3 was localized on the cell surface as well as in the cytoplasm. Sf9 cells infected with recombinant virus underwent homotypic aggregation in the presence of exogenous glycoprotein (i.e., asialofetuin), whereas control cells uninfected or infected with wild-type virus did not. Lactose and Fab' fragments of anti-Gal-3 antibodies markedly inhibited the cell-cell aggregation. Moreover, cosuspension of Sf9 cells infected with the recombinant virus with uninfected cells in the presence of asialofetuin resulted in a preferential cell-cell adhesion of the Gal-3-expressing cells. These results directly demonstrate the ability of cell surface Gal-3 molecules to mediate homotypic cell adhesion by bridging through branched, soluble complementary glycoconjugates.
1 This work was supported by NIH Grant R01-CA46120. A. R. is the recipient of the Paul Zuckerman Support Foundation Fund for Cancer Research.
2 Present address: Department of Otolaryngology, Osaka University Medical School, 2–2 Yamadaoka, Suita, Osaka 565, Japan.
3 To whom requests for reprints should be addressed, at Metastasis Research Program, Michigan Cancer Foundation, 110 East Warren Avenue, Detroit, MI 48201.
Received 5/10/95. Accepted 6/15/95.
This article has been cited by other articles:
|
|
 |
|
  P. Argueso, A. Guzman-Aranguez, F. Mantelli, Z. Cao, J. Ricciuto, and N. Panjwani Association of Cell Surface Mucins with Galectin-3 Contributes to the Ocular Surface Epithelial Barrier J. Biol. Chem., August 21, 2009; 284(34): 23037 - 23045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Gunning, R. J. M. Bongaerts, and V. J. Morris Recognition of galactan components of pectin by galectin-3 FASEB J, February 1, 2009; 23(2): 415 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kang, K. Moon, E. Lee, Y. Lee, E. Lee, C Ahn, and Y. Song Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis Lupus, January 1, 2009; 18(1): 22 - 28. [Abstract] [PDF]
|
|
|
|
 |
|
 I. IURISCI, A. CUMASHI, A. A. SHERMAN, Y. E. TSVETKOV, N. TINARI, E. PICCOLO, M. D'EGIDIO, V. ADAMO, C. NATOLI, G. A. RABINOVICH, et al. Synthetic Inhibitors of Galectin-1 and -3 Selectively Modulate Homotypic Cell Aggregation and Tumor Cell Apoptosis Anticancer Res, January 1, 2009; 29(1): 403 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Kumar and S. L. Deutscher 111In-Labeled Galectin-3-Targeting Peptide as a SPECT Agent for Imaging Breast Tumors J. Nucl. Med., May 1, 2008; 49(5): 796 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Henderson, A. C. Mackinnon, S. L. Farnworth, F. Poirier, F. P. Russo, J. P. Iredale, C. Haslett, K. J. Simpson, and T. Sethi Galectin-3 regulates myofibroblast activation and hepatic fibrosis PNAS, March 28, 2006; 103(13): 5060 - 5065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukumori, N. Oka, Y. Takenaka, P. Nangia-Makker, E. Elsamman, T. Kasai, M. Shono, H.-o. Kanayama, J. Ellerhorst, R. Lotan, et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res., March 15, 2006; 66(6): 3114 - 3119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Iacobini, G. Oddi, S. Menini, L. Amadio, C. Ricci, C. Di Pippo, M. Sorcini, F. Pricci, F. Pugliese, and G. Pugliese Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice Am J Physiol Renal Physiol, September 1, 2005; 289(3): F611 - F621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shimura, Y. Takenaka, T. Fukumori, S. Tsutsumi, K. Okada, V. Hogan, A. Kikuchi, H. Kuwano, and A. Raz Implication of Galectin-3 in Wnt Signaling Cancer Res., May 1, 2005; 65(9): 3535 - 3537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zou, V. V. Glinsky, L. A. Landon, L. Matthews, and S. L. Deutscher Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion Carcinogenesis, February 1, 2005; 26(2): 309 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fukumori, Y. Takenaka, T. Yoshii, H.-R. C. Kim, V. Hogan, H. Inohara, S. Kagawa, and A. Raz CD29 and CD7 Mediate Galectin-3-Induced Type II T-Cell Apoptosis Cancer Res., December 1, 2003; 63(23): 8302 - 8311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. Glinsky, G. V. Glinsky, O. V. Glinskii, V. H. Huxley, J. R. Turk, V. V. Mossine, S. L. Deutscher, K. J. Pienta, and T. P. Quinn Intravascular Metastatic Cancer Cell Homotypic Aggregation at the Sites of Primary Attachment to the Endothelium Cancer Res., July 1, 2003; 63(13): 3805 - 3811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. John, H. Leffler, B. Kahl-Knutsson, I. Svensson, and G. A. Jarvis Truncated Galectin-3 Inhibits Tumor Growth and Metastasis in Orthotopic Nude Mouse Model of Human Breast Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2374 - 2383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Maeda, N. Kawada, S. Seki, T. Arakawa, K. Ikeda, H. Iwao, H. Okuyama, J. Hirabayashi, K.-i. Kasai, and K. Yoshizato Stimulation of Proliferation of Rat Hepatic Stellate Cells by Galectin-1 and Galectin-3 through Different Intracellular Signaling Pathways J. Biol. Chem., May 23, 2003; 278(21): 18938 - 18944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Lehtonen, M Kiuru, A Rokman, T Ikonen, J M Cunningham, D J Schaid, M Matikainen, N N Nupponen, A Karhu, O-P Kallioniemi, et al. No fumarate hydratase (FH) mutations in hereditary prostate cancer J. Med. Genet., March 1, 2003; 40(3): e19 - 19. [Full Text] [PDF]
|
|
|
|
 |
|
 V. J. Bernet, J. Anderson, Y. Vaishnav, B. Solomon, C. F. Adair, M. Saji, K. D. Burman, H. B. Burch, and M. D. Ringel Determination of Galectin-3 Messenger Ribonucleic Acid Overexpression in Papillary Thyroid Cancer by Quantitative Reverse Transcription-Polymerase Chain Reaction J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4792 - 4796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shimamura, M. Sakamoto, Y. Ino, K. Shimada, T. Kosuge, Y. Sato, K. Tanaka, H. Sekihara, and S. Hirohashi Clinicopathological Significance of Galectin-3 Expression in Ductal Adenocarcinoma of the Pancreas Clin. Cancer Res., August 1, 2002; 8(8): 2570 - 2575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshii, T. Fukumori, Y. Honjo, H. Inohara, H.-R. C. Kim, and A. Raz Galectin-3 Phosphorylation Is Required for Its Anti-apoptotic Function and Cell Cycle Arrest J. Biol. Chem., February 22, 2002; 277(9): 6852 - 6857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mengwasser, F.-T. Liu, and J. P. Sleeman Galectin-3 is strongly up-regulated in nonapoptosing mammary epithelial cells during rat mammary gland involution Glycobiology, February 1, 2002; 12(2): 129 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Visegrady, N. G. Than, F. Kilar, B. Sumegi, G. N. Than, and H. Bohn Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin-13) Protein Eng. Des. Sel., November 1, 2001; 14(11): 875 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. Glinsky, G. V. Glinsky, K. Rittenhouse-Olson, M. E. Huflejt, O. V. Glinskii, S. L. Deutscher, and T. P. Quinn The Role of Thomsen-Friedenreich Antigen in Adhesion of Human Breast and Prostate Cancer Cells to the Endothelium Cancer Res., June 1, 2001; 61(12): 4851 - 4857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-G. Joo, P. S Goedegebuure, N. Sadanaga, M. Nagoshi, W. von Bernstorff, and T. J. Eberlein Expression and function of galectin-3, a {beta}-galactoside-binding protein in activated T lymphocytes J. Leukoc. Biol., April 1, 2001; 69(4): 555 - 564. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Honjo, H. Inohara, S. Akahani, T. Yoshii, Y. Takenaka, J.-i. Yoshida, K. Hattori, Y. Tomiyama, A. Raz, and T. Kubo Expression of Cytoplasmic Galectin-3 as a Prognostic Marker in Tongue Carcinoma Clin. Cancer Res., December 1, 2000; 6(12): 4635 - 4640. [Abstract] [Full Text]
|
|
|
|
|
|
D. Sanmugalingam, A. J. Wardlaw, and P. Bradding Adhesion of human lung mast cells to bronchial epithelium: evidence for a novel carbohydrate-mediated mechanism J. Leukoc. Biol., July 1, 2000; 68(1): 38 - 46. [Abstract] [Full Text]
|
|
|
|
|
|
I. Iurisci, N. Tinari, C. Natoli, D. Angelucci, E. Cianchetti, and S. Iacobelli Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients Clin. Cancer Res., April 1, 2000; 6(4): 1389 - 1393. [Abstract] [Full Text]
|
|
|
|
|
|
H. C. Gong, Y. Honjo, P. Nangia-Makker, V. Hogan, N. Mazurak, R. S. Bresalier, and A. Raz The NH2 Terminus of Galectin-3 Governs Cellular Compartmentalization and Functions in Cancer Cells Cancer Res., December 1, 1999; 59(24): 6239 - 6245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Seetharaman, A. Kanigsberg, R. Slaaby, H. Leffler, S. H. Barondes, and J. M. Rini X-ray Crystal Structure of the Human Galectin-3 Carbohydrate Recognition Domain at 2.1-A Resolution J. Biol. Chem., May 22, 1998; 273(21): 13047 - 13052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Tureci, H. Schmitt, N. Fadle, M. Pfreundschuh, and U. Sahin Molecular Definition of a Novel Human Galectin Which Is Immunogenic in Patients with Hodgkin's Disease J. Biol. Chem., March 7, 1997; 272(10): 6416 - 6422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mazurek, J. Conklin, J. C. Byrd, A. Raz, and R. S. Bresalier Phosphorylation of the beta -Galactoside-binding Protein Galectin-3 Modulates Binding to Its Ligands J. Biol. Chem., November 10, 2000; 275(46): 36311 - 36315. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
